Pre-made Naratuximab benchmark antibody ( Whole mAb ADC, anti-CD37 therapeutic antibody, Anti-GP52-40/TSPAN26 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Naratuximab biosimilar, Whole mAb ADC, Anti-CD37 Antibody: Anti-GP52-40/TSPAN26 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Naratuximab emtansine | IMGN529 (K7153A) | Debio 1562 | Drug Description. ... The investigational drug is in clinical trials for the potential treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, B-Cell Lymphomas. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-364-1mg	1mg	Inquiry
GMP-Bios-ab-364-10mg	10mg	Inquiry
GMP-Bios-ab-364-100mg	100mg	Inquiry
GMP-Bios-ab-364-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Naratuximab biosimilar, Whole mAb ADC, Anti-CD37 Antibody: Anti-GP52-40/TSPAN26 therapeutic antibody
INN Name	Naratuximab
Target	CD37
Format	Whole mAb ADC
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	ImmunoGen;Chronic lymphocytic leukaemia
Conditions Approved	na
Conditions Active	Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma
Conditions Discontinued	Chronic lymphocytic leukaemia
Development Tech	na